These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34130573)

  • 1. Clinical, patient and estimated cost benefits of proactive management versus reactive management with calcipotriol/betamethasone dipropionate foam for the treatment of plaque psoriasis in Finland.
    Harvima RJ; Gooderham M; Tyring S; Thoning H; Nyholm N; Stein Gold L
    J Dermatolog Treat; 2022 Jun; 33(4):2234-2240. PubMed ID: 34130573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
    Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
    J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis.
    Papp K; Adamski Z; Guenther L; Liljedahl M; Miasik-Pogodzinska A; Szponar-Bojda A; Lynde C; Nutt T; Mørch MH; Tyring S; Werschler W; Reich A; Sadick N; Turchin I; Lacour JP
    J Dermatolog Treat; 2022 Jun; 33(4):2297-2304. PubMed ID: 34365872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
    Foley P; Garrett S; Ryttig L
    Curr Med Res Opin; 2018 Jul; 34(7):1277-1283. PubMed ID: 29336190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis.
    Stein Gold L; Alonso-Llamazares J; Lacour JP; Warren RB; Tyring SK; Kircik L; Yamauchi P; Lebwohl M;
    Adv Ther; 2020 Nov; 37(11):4730-4753. PubMed ID: 32965655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG.
    Jalili A; Calzavara-Pinton P; Kircik L; Lons-Danic D; Pink A; Tyring S; de la Cueva P; Gooderham M; Segaert S; Nyholm N; Thoning H; Petersen B; Thaçi D
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):60-67. PubMed ID: 34543474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect on BSA of Proactive Management versus Reactive Management of Psoriasis With Fixed-Dose Cal/BD Foam in the PSO-LONG Study.
    Takhar A; Thoning H; Nyholm N; Petersen B; Stein Gold L
    J Drugs Dermatol; 2021 May; 20(5):567-570. PubMed ID: 33938704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease.
    Pink AE; Jalili A; Berg P; Calzavara-Pinton PG; de la Cueva Dobao P; Thaçi D; Torpet M; Jensen KL; Segaert S
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1116-1123. PubMed ID: 30916417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
    Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
    Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
    Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
    Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
    Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
    J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study.
    Griffiths CE; Stein Gold L; Cambazard F; Kalb RE; Lowson D; Møller A; Paul C
    Eur J Dermatol; 2018 Jun; 28(3):356-363. PubMed ID: 29952297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
    Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial.
    Guenther L; Takhar A; Megna M; Sebastian M; Nyholm N; Thoning H; Levin LÅ
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):1054-1063. PubMed ID: 35297108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
    Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
    J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries.
    Balak DMW; Carrascosa JM; Gregoriou S; Calzavara-Pinton P; Bewley A; Antunes J; Nyeland ME; Viola MG; Sawyer LM; Becla L
    J Dermatolog Treat; 2021 Nov; 32(7):701-708. PubMed ID: 31940225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
    Fabbrocini G; Dauden E; Jalili A; Bewley A
    G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis.
    Papp KA; Thoning H; Gerdes S; Megna M; Brandi H; Jablonski Bernasconi MY; Yélamos O
    J Dermatolog Treat; 2022 Nov; 33(7):3005-3013. PubMed ID: 35875991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of an innovative aerosol foam formulation of fixed combination calcipotriol plus betamethasone dipropionate in patients with psoriasis vulgaris.
    Queille-Roussel C; Olesen M; Villumsen J; Lacour JP
    Clin Drug Investig; 2015 Apr; 35(4):239-45. PubMed ID: 25708531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.
    Gold LS; Hansen JB; Patel D; Veverka KA; Strober B
    J Am Acad Dermatol; 2020 Jul; 83(1):131-138. PubMed ID: 32430142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.